
    
      After selecting patients who satisfied the inclusion criteria and were not disqualified by
      the exclusion criteria, through a double-blind procedure the patients are directed to orally
      take either the investigational drug melatonin or a placebo(allocation ratio 1:1) for 4
      weeks, once daily, before going to sleep. The evaluation of efficacy and safety is performed
      at the first baseline and immediately after administering the drug for 4 weeks.
    
  